Zhejiang Huahai Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Zhejiang Huahai Pharmaceutical has a total shareholder equity of CN¥9.0B and total debt of CN¥6.9B, which brings its debt-to-equity ratio to 77.1%. Its total assets and total liabilities are CN¥19.6B and CN¥10.6B respectively. Zhejiang Huahai Pharmaceutical's EBIT is CN¥1.8B making its interest coverage ratio 10.7. It has cash and short-term investments of CN¥1.5B.
Key information
77.1%
Debt to equity ratio
CN¥6.91b
Debt
| Interest coverage ratio | 10.7x |
| Cash | CN¥1.52b |
| Equity | CN¥8.95b |
| Total liabilities | CN¥10.60b |
| Total assets | CN¥19.56b |
Recent financial health updates
Here's Why Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Meaningful Debt Burden
Sep 25
Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt
May 28Recent updates
Investors Holding Back On Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521)
Oct 22Here's Why Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Meaningful Debt Burden
Sep 25Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 20Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt
May 28There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings
May 06Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel
Mar 22Financial Position Analysis
Short Term Liabilities: 600521's short term assets (CN¥8.0B) exceed its short term liabilities (CN¥5.7B).
Long Term Liabilities: 600521's short term assets (CN¥8.0B) exceed its long term liabilities (CN¥4.9B).
Debt to Equity History and Analysis
Debt Level: 600521's net debt to equity ratio (60.2%) is considered high.
Reducing Debt: 600521's debt to equity ratio has increased from 76.8% to 77.1% over the past 5 years.
Debt Coverage: 600521's debt is well covered by operating cash flow (38.3%).
Interest Coverage: 600521's interest payments on its debt are well covered by EBIT (10.7x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 01:37 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Huahai Pharmaceutical Co., Ltd. is covered by 25 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Yue Gao | Changjiang Securities Co. LTD. |
| Xiyuan Liu | China International Capital Corporation Limited |